Variables | Non-AKI | AKI stage 1 | AKI stage 2 | AKI stage 3 | P |
---|---|---|---|---|---|
N | 703 (83.5) | 75 (8.9) | 31 (3.7) | 33 (3.9) | Â |
 Age, years | 65.0 ± 12.6 | 74.8 ± 11.2 | 76.2 ± 9.3 | 69.2 ± 15.7 |  < 0.001 |
 Males, n (%) | 177 (25.2) | 22 (29.3) | 12 (38.7) | 11 (33.3) | 0.250 |
 BMI, kg/m2 | 24.2 ± 2.7 | 23.4 ± 2.3 | 23.7 ± 1.6 | 23.8 ± 2.6 | 0.066 |
 Smoking, n (%) | 328 (46.7) | 33 (44) | 9 (29) | 12 (36.4) | 0.176 |
 Drinking, n (%) | 181 (25.9) | 15 (20) | 7 (22.6) | 10 (30.3) | 0.619 |
 Hypertension, n (%) | 391 (55.6) | 47 (62.7) | 22 (71) | 27 (81.8) | 0.007 |
 Diabetes, n (%) | 193 (27.5) | 33 (44) | 16 (51.6) | 16 (48.5) |  < 0.001 |
 Hyperlipidemia, n (%) | 72 (10.2) | 8 (10.7) | 2 (6.5) | 4 (12.1) | 0.890 |
 SBP, mmHg | 132.4 ± 23.4 | 130.4 ± 29.1 | 132.6 ± 29.9 | 142.3 ± 29.3 | 0.116 |
 DBP, mmHg | 81 ± 15.1 | 78.2 ± 20 | 74.8 ± 21.3 | 83.9 ± 24 | 0.061 |
 Heart rate, /min | 78.8 ± 16.1 | 85.1 ± 25 | 82.5 ± 25.7 | 85.7 ± 17.5 | 0.003 |
 Killip class ≥ 1, n (%) | 315 (44.8) | 43 (57.3) | 23 (74.2) | 17 (51.5) | 0.003 |
 STEMI, n (%) | 303 (43.1) | 32 (42.7) | 13 (41.9) | 10 (30.3) | 0.548 |
Laboratory findings | |||||
 WBC, 109/L | 9.0 ± 3.3 | 10.5 ± 5.5 | 11.8 ± 4.1 | 8.9 ± 3.9 |  < 0.001 |
 Neutrophil, 109/L | 6.8 ± 3.2 | 8.3 ± 5.2 | 9.5 ± 4 | 7.1 ± 3.6 |  < 0.001 |
 Hemoglobin, g/L | 136.3 ± 19.5 | 120.8 ± 22.9 | 113.8 ± 23.2 | 101.8 ± 25.5 |  < 0.001 |
 Platelet count, 109/L | 179 (142–226) | 182 (133–217) | 219 (126–273) | 181 (145–246) | 0.638 |
 Fibrinogen, g/L | 3.5 ± 1.3 | 3.9 ± 1.4 | 4.1 ± 1.2 | 5.2 ± 1.9 |  < 0.001 |
 Blood glucose, mmol/L | 8.8 ± 4.2 | 11.1 ± 5.8 | 11.4 ± 7.3 | 9.8 ± 4.4 |  < 0.001 |
 Creatinine, μmol/L | 76 (64–88) | 129 (119–150) | 195 (167–210) | 327 (250–586) |  < 0.001 |
 eGFR | 85.6 ± 18.1 | 42.6 ± 6.7 | 29.6 ± 15.3 | 19.4 ± 22.5 |  < 0.001 |
 BUN, mmol/L | 5.3 (4.4–6.7) | 8.9 (7.3–12.2) | 13.9 (10.9–16.3) | 19 (13.5–25.4) |  < 0.001 |
 Triglycerides, mmol/L | 1.49 (1.05–2.18) | 1.33 (0.98–2.02) | 1.41 (1.19–2.04) | 1.68 (1.24–2.53) | 0.290 |
 Total cholesterol, mmol/L | 4.4 ± 1.2 | 4.2 ± 1 | 4.3 ± 1.5 | 4.4 ± 1.7 | 0.710 |
 HDL-C, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.4 | 1.2 ± 0.4 | 1.1 ± 0.4 | 0.541 |
 LDL-C, mmol/L | 2.7 ± 1 | 2.5 ± 0.8 | 2.6 ± 1.3 | 2.6 ± 1.4 | 0.327 |
 NT-proBNP, pg/mL | 685 (180–2317) | 4585 (1344–12382) | 7530 (3711–22358) | 13281 (4382–35000) |  < 0.001 |
 Hs-CTnT,pg/mL | 308 (38–1385) | 568 (54–2555) | 1287 (616–4284) | 914 (185–4961) |  < 0.001 |
Admission medication | |||||
 Aspirin, n (%) | 691 (98.3) | 73 (97.3) | 29 (93.5) | 31 (93.9) | 0.116 |
 Dual antiplatelet, n (%) | 638 (90.8) | 68 (90.7) | 29 (93.5) | 26 (78.8) | 0.134 |
 β receptor blockers, n (%) | 404 (57.5) | 27 (36.0) | 15 (48.4) | 17 (51.5) | 0.004 |
 Statin, n (%) | 660 (93.9) | 56 (74.7) | 25 (80.6) | 29 (87.9) |  < 0.001 |
 ACEI or ARB, n (%) | 285 (40.5) | 18 (24.0) | 9 (29.0) | 7 (21.2) | 0.004 |
Percutaneous coronary intervention | |||||
 Contrast dose, ml | 98.8 ± 14.5 | 112.9 ± 12.5 | 132.9 ± 15.7 | 147.3 ± 21.6 |  < 0.001 |
 Stent ≥ 2, n (%) | 207 (32.9) | 19 (31.7) | 13 (50) | 13 (41.9) | 0.227 |
 Three-vessel disease, n (%) | 352 (50.1) | 35 (46.7) | 14 (45.2) | 21 (63.6) | 0.380 |
Risk score | |||||
 GRACE score | 135 ± 34.1 | 151.9 ± 36.3 | 173.1 ± 39.5 | 182.8 ± 40.0 |  < 0.001 |
 Gensini score | 51 (24–79) | 58 (17–82) | 68 (43–101) | 89 (45–68) | 0.020 |
 Mehran risk score | 9.6 ± 4.8 | 14 ± 4.8 | 15.2 ± 4.7 | 16.2 ± 4.4 |  < 0.001 |